Nautilus Biotechnology, Inc. (NASDAQ: NAUT – Get Rating) – Equities researchers at Jefferies Financial Group boosted their Q3 2022 EPS estimates for shares of Nautilus Biotechnology in a research note issued to investors on Wednesday, August 3rd. Jefferies Financial Group analyst B. Couillard now forecasts that the company will post earnings of ($ 0.14) per share for the quarter, up from their prior forecast of ($ 0.16). The consensus estimate for Nautilus Biotechnology’s current full-year earnings is ($ 0.59) per share. Jefferies Financial Group also issued estimates for Nautilus Biotechnology’s Q4 2022 earnings at ($ 0.16) EPS, FY2022 earnings at ($ 0.54) EPS, Q1 2023 earnings at ($ 0.16) EPS, Q2 2023 earnings at ($ 0.17) EPS, Q3 2023 earnings at ($ 0.17 ) EPS, Q4 2023 earnings at ($ 0.17) EPS and FY2023 earnings at ($ 0.67) EPS.
Nautilus Biotechnology (NASDAQ: NAUT – Get Rating) last released its quarterly earnings data on Tuesday, May 3rd. The company reported ($ 0.13) earnings per share for the quarter, topping the consensus estimate of ($ 0.15) by $ 0.02.
NAUT has been the subject of several other research reports. The Goldman Sachs Group lowered their target price on shares of Nautilus Biotechnology from $ 4.00 to $ 2.00 and set a “neutral” rating for the company in a report on Wednesday. Morgan Stanley lowered their target price on shares of Nautilus Biotechnology from $ 8.00 to $ 6.00 and set an “equal weight” rating for the company in a report on Wednesday.
Nautilus Biotechnology Trading Up 4.3%
NAUT opened at $ 2.94 on Friday. The company’s fifty day moving average price is $ 2.97 and its two-hundred day moving average price is $ 3.65. Nautilus Biotechnology has a 1-year low of $ 2.53 and a 1-year high of $ 8.61. The company has a market cap of $ 365.92 million, a price-to-earnings ratio of -5.64 and a beta of 0.96.
Hedge Funds Weigh In On Nautilus Biotechnology
Large investors have recently modified their holdings of the company. Mirabella Financial Services LLP bought a new position in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $ 75,000. Shay Capital LLC bought a new position in shares of Nautilus Biotechnology in the fourth quarter valued at approximately $ 107,000. Affinity Asset Advisors LLC raised its stake in Nautilus Biotechnology by 7.7% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,049,721 shares of the company’s stock valued at $ 5,438,000 after purchasing an additional 74,721 shares in the last quarter. Tikvah Management LLC raised its stake in Nautilus Biotechnology by 73.9% in the fourth quarter. Tikvah Management LLC now owns 1,231,835 shares of the company’s stock valued at $ 6,381,000 after purchasing an additional 523,295 shares in the last quarter. Finally, Perceptive Advisors LLC raised its stake in Nautilus Biotechnology by 2.2% in the fourth quarter. Perceptive Advisors LLC now owns 9,111,151 shares of the company’s stock valued at $ 47,195,000 after purchasing an additional 200,000 shares in the last quarter. 47.89% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Nautilus Biotechnology news, CEO Sujal M. Patel bought 50,000 shares of the business’s stock in a transaction on Monday, May 9th. The stock was purchased at an average price of $ 3.96 per share, for a total transaction of $ 198,000.00. Following the completion of the transaction, the chief executive officer now directly owns 9,964,488 shares of the company’s stock, valued at $ 39,459,372.48. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 41.30% of the company’s stock.
About Nautilus Biotechnology
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Receive News & Ratings for Nautilus Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nautilus Biotechnology and related companies with MarketBeat.com’s FREE daily email newsletter.